<p>拥有大量资金的投资者对 <strong>AbbVie</strong> (NYSE: ABBV) 持乐观态度。</p>
<p>而散户交易者应该知道这一点。</p>
<p>我们今天注意到这一点，当交易出现在我们在 Benzinga 跟踪的公开可用期权历史记录中。</p>
<p>无论这些是机构还是仅仅是富有的个人，我们都不知道。但当 ABBV 发生如此重大的事情时，通常意味着有人知道即将发生什么。</p>
<p>那么我们如何知道这些投资者刚刚做了什么呢？</p>
<p>今天，Benzinga 的期权扫描仪发现了 16 笔不寻常的 AbbVie 期权交易。</p>
<p>这并不正常。</p>
<p>这些大资金交易者的整体情绪在 43% 看涨和 43% 看跌之间分裂。</p>
<p>在我们发现的所有特殊期权中，有 2 笔是看跌期权，总金额为 $97,520，14 笔是看涨期权，总金额为 $1,449,383。</p>
<h3>预期价格变动</h3>
<p>在评估交易量和未平仓合约后，很明显主要市场参与者正在关注 AbbVie 的价格区间在 $120.0 到 $250.0 之间，涵盖了过去三个月。</p>
<h3>交易量与未平仓合约发展</h3>
<p>查看交易量和未平仓合约是对股票进行尽职调查的一个有洞察力的方法。</p>
<p>这些数据可以帮助你跟踪 AbbVie 期权在特定行权价的流动性和兴趣。</p>
<p>下面，我们可以观察到在过去 30 天内，AbbVie 在 $120.0 到 $250.0 的行权价范围内的看涨和看跌期权的交易量和未平仓合约的演变。</p>
<h3>AbbVie 30 天期权交易量与兴趣快照</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766001684_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期权看涨图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766001684_0.png"/></p>
<h3>发现的最大期权：</h3>
<table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行权价</strong></th>
<th><strong>总交易价格</strong></th>
<th><strong>未平仓合约</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.6</td>
<td>$14.66</td>
<td>$220.00</td>
<td>$293.4K</td>
<td>1.1K</td>
<td align="right">461</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看涨</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$230.00</td>
<td>$226.5K</td>
<td>5.7K</td>
<td align="right">638</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$220.00</td>
<td>$190.9K</td>
<td>1.1K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.72</td>
<td>$220.00</td>
<td>$183.3K</td>
<td>1.1K</td>
<td align="right">6</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.7</td>
<td>$14.75</td>
<td>$220.00</td>
<td>$173.9K</td>
<td>1.1K</td>
<td align="right">579</td>
</tr>
</tbody>
</table>
<h3>关于 AbbVie</h3>
<p>AbbVie 是一家制药公司，强烈关注免疫学（包括 Humira、Skyrizi 和 Rinvoq）和肿瘤学（包括 Imbruvica 和 Venclexta）。该公司于 2013 年初从 Abbott 分拆而出。2020 年收购 Allergan 增加了多个新产品和药物，包括 Botox。2024 年收购 Cerevel（神经科学）和 ImmunoGen（肿瘤学）进一步补充了 AbbVie 的产品组合。</p>
<p>在分析了与 AbbVie 相关的期权活动后，我们转向更仔细地观察公司的自身表现。</p>
<h3>AbbVie 目前的状况如何？</h3>
<ul>
<li>ABBV 的交易量为 2,394,007，价格上涨 0.97%，达到 $225.83。</li>
<li>当前 RSI 值表明该股票在超买和超卖之间处于中性状态。</li>
<li>下一次财报预计在 44 天后发布。</li>
</ul>
<h3>专家对 AbbVie 的看法</h3>
<p>2 位市场专家最近对该股票发布了评级，目标价格共识为 $267.0。</p>
<p><strong>在短短 20 天内将 $1000 变成 $1270？</strong></p>
<p>一位拥有 20 年经验的专业期权交易员揭示了他的单行图表技术，显示何时买入和卖出。复制他的交易，平均每 20 天获得 27% 的利润。点击这里获取访问权限。
* 在评估中保持一致，摩根士丹利的一位分析师对 AbbVie 维持超配评级，目标价格为 $269。
* 在积极的举措中，汇丰银行的一位分析师将其评级上调至买入，并将目标价格调整为 $265。</p>
<p>与仅交易股票相比，期权是一种风险更高的资产，但它们具有更高的利润潜力。严肃的期权交易者通过每天学习、逐步进出交易、关注多个指标以及密切关注市场来管理这种风险。</p>
<p>如果你想及时了解 AbbVie 最新的期权交易，Benzinga Pro 为你提供实时期权交易警报。</p>

艾伯维

<p>拥有大量资本的投资者对艾伯维（NYSE:ABBV）采取了看涨的态度，这从异常的期权活动中可以看出。Benzinga 的期权扫描仪识别出 16 笔不寻常的交易，情绪分布为 43% 看涨和 43% 看跌。主要市场参与者关注的价格区间在$120.0 到$250.0 之间。艾伯维是一家制药公司，目前的交易量为 2,394,007，股价为$225.83。摩根士丹利和汇丰的分析师给予了积极的评级，目标价格分别为$269 和$265</p>

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>AbbVie</strong> (NYSE: ABBV).</p>
<div class="lb-trans"><p>拥有大量资金的投资者对 <strong>AbbVie</strong> (NYSE: ABBV) 持乐观态度。</p>
</div><p>And retail traders should know.</p>
<div class="lb-trans"><p>而散户交易者应该知道这一点。</p>
</div><p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<div class="lb-trans"><p>我们今天注意到这一点，当交易出现在我们在 Benzinga 跟踪的公开可用期权历史记录中。</p>
</div><p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.</p>
<div class="lb-trans"><p>无论这些是机构还是仅仅是富有的个人，我们都不知道。但当 ABBV 发生如此重大的事情时，通常意味着有人知道即将发生什么。</p>
</div><p>So how do we know what these investors just did?</p>
<div class="lb-trans"><p>那么我们如何知道这些投资者刚刚做了什么呢？</p>
</div><p>Today, Benzinga's options scanner spotted 16 uncommon options trades for AbbVie.</p>
<div class="lb-trans"><p>今天，Benzinga 的期权扫描仪发现了 16 笔不寻常的 AbbVie 期权交易。</p>
</div><p>This isn't normal.</p>
<div class="lb-trans"><p>这并不正常。</p>
</div><p>The overall sentiment of these big-money traders is split between 43% bullish and 43%, bearish.</p>
<div class="lb-trans"><p>这些大资金交易者的整体情绪在 43% 看涨和 43% 看跌之间分裂。</p>
</div><p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $97,520, and 14 are calls, for a total amount of $1,449,383.</p>
<div class="lb-trans"><p>在我们发现的所有特殊期权中，有 2 笔是看跌期权，总金额为 $97,520，14 笔是看涨期权，总金额为 $1,449,383。</p>
</div><h3>Expected Price Movements</h3>
<div class="lb-trans"><h3>预期价格变动</h3>
</div><p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $250.0 for AbbVie, spanning the last three months.</p>
<div class="lb-trans"><p>在评估交易量和未平仓合约后，很明显主要市场参与者正在关注 AbbVie 的价格区间在 $120.0 到 $250.0 之间，涵盖了过去三个月。</p>
</div><h3>Volume &amp; Open Interest Development</h3>
<div class="lb-trans"><h3>交易量与未平仓合约发展</h3>
</div><p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<div class="lb-trans"><p>查看交易量和未平仓合约是对股票进行尽职调查的一个有洞察力的方法。</p>
</div><p>This data can help you track the liquidity and interest for AbbVie's options for a given strike price.</p>
<div class="lb-trans"><p>这些数据可以帮助你跟踪 AbbVie 期权在特定行权价的流动性和兴趣。</p>
</div><p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $120.0 to $250.0 in the last 30 days.</p>
<div class="lb-trans"><p>下面，我们可以观察到在过去 30 天内，AbbVie 在 $120.0 到 $250.0 的行权价范围内的看涨和看跌期权的交易量和未平仓合约的演变。</p>
</div><h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<div class="lb-trans"><h3>AbbVie 30 天期权交易量与兴趣快照</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766001684_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2025/1766001684_0.png"/></p>
<h3>Biggest Options Spotted:</h3>
<div class="lb-trans"><h3>发现的最大期权：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.6</td>
<td>$14.66</td>
<td>$220.00</td>
<td>$293.4K</td>
<td>1.1K</td>
<td align="right">461</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$230.00</td>
<td>$226.5K</td>
<td>5.7K</td>
<td align="right">638</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$220.00</td>
<td>$190.9K</td>
<td>1.1K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.72</td>
<td>$220.00</td>
<td>$183.3K</td>
<td>1.1K</td>
<td align="right">6</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.7</td>
<td>$14.75</td>
<td>$220.00</td>
<td>$173.9K</td>
<td>1.1K</td>
<td align="right">579</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行权价</strong></th>
<th><strong>总交易价格</strong></th>
<th><strong>未平仓合约</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.6</td>
<td>$14.66</td>
<td>$220.00</td>
<td>$293.4K</td>
<td>1.1K</td>
<td align="right">461</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看涨</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$230.00</td>
<td>$226.5K</td>
<td>5.7K</td>
<td align="right">638</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.65</td>
<td>$14.7</td>
<td>$220.00</td>
<td>$190.9K</td>
<td>1.1K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.6</td>
<td>$14.72</td>
<td>$220.00</td>
<td>$183.3K</td>
<td>1.1K</td>
<td align="right">6</td>
</tr>
<tr>
<td>ABBV</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>03/20/26</td>
<td>$14.85</td>
<td>$14.7</td>
<td>$14.75</td>
<td>$220.00</td>
<td>$173.9K</td>
<td>1.1K</td>
<td align="right">579</td>
</tr>
</tbody>
</table>
</div><h3>About AbbVie</h3>
<div class="lb-trans"><h3>关于 AbbVie</h3>
</div><p>AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.</p>
<div class="lb-trans"><p>AbbVie 是一家制药公司，强烈关注免疫学（包括 Humira、Skyrizi 和 Rinvoq）和肿瘤学（包括 Imbruvica 和 Venclexta）。该公司于 2013 年初从 Abbott 分拆而出。2020 年收购 Allergan 增加了多个新产品和药物，包括 Botox。2024 年收购 Cerevel（神经科学）和 ImmunoGen（肿瘤学）进一步补充了 AbbVie 的产品组合。</p>
</div><p>Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.</p>
<div class="lb-trans"><p>在分析了与 AbbVie 相关的期权活动后，我们转向更仔细地观察公司的自身表现。</p>
</div><h3>Where Is AbbVie Standing Right Now?</h3>
<div class="lb-trans"><h3>AbbVie 目前的状况如何？</h3>
</div><ul>
<li>With a trading volume of 2,394,007, the price of ABBV is up by 0.97%, reaching $225.83.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 44 days from now.</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 的交易量为 2,394,007，价格上涨 0.97%，达到 $225.83。</li>
<li>当前 RSI 值表明该股票在超买和超卖之间处于中性状态。</li>
<li>下一次财报预计在 44 天后发布。</li>
</ul>
</div><h3>What The Experts Say On AbbVie</h3>
<div class="lb-trans"><h3>专家对 AbbVie 的看法</h3>
</div><p>2 market experts have recently issued ratings for this stock, with a consensus target price of $267.0.</p>
<div class="lb-trans"><p>2 位市场专家最近对该股票发布了评级，目标价格共识为 $267.0。</p>
</div><p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<div class="lb-trans"><p><strong>在短短 20 天内将 $1000 变成 $1270？</strong></p>
</div><p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $269.
* In a positive move, an analyst from HSBC has upgraded their rating to Buy and adjusted the price target to $265.</p>
<div class="lb-trans"><p>一位拥有 20 年经验的专业期权交易员揭示了他的单行图表技术，显示何时买入和卖出。复制他的交易，平均每 20 天获得 27% 的利润。点击这里获取访问权限。
* 在评估中保持一致，摩根士丹利的一位分析师对 AbbVie 维持超配评级，目标价格为 $269。
* 在积极的举措中，汇丰银行的一位分析师将其评级上调至买入，并将目标价格调整为 $265。</p>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>与仅交易股票相比，期权是一种风险更高的资产，但它们具有更高的利润潜力。严肃的期权交易者通过每天学习、逐步进出交易、关注多个指标以及密切关注市场来管理这种风险。</p>
</div><p>If you want to stay updated on the latest options trades for AbbVie, Benzinga Pro gives you real-time options trades alerts.</p>
<div class="lb-trans"><p>如果你想及时了解 AbbVie 最新的期权交易，Benzinga Pro 为你提供实时期权交易警报。</p>
</div>

观察艾伯维最近异常的期权交易活动